Fig. 2: Difference in proportions of patients experiencing meaningful improvement from baseline (PRO-evaluable population). | Leukemia

Fig. 2: Difference in proportions of patients experiencing meaningful improvement from baseline (PRO-evaluable population).

From: Patient-reported outcomes in Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinib: results from the PhALLCON trial

Fig. 2

A Meaningful improvement from baseline to end of induction. B Meaningful improvement from baseline to end of consolidation. Domains/subscales in bold are primary domains of interest. “N” indicates the number of patients in the PRO-evaluable population who were at risk of the event of interest (meaningful improvement) and had a non-missing score change at the time point of interest, and “n” indicates the number of patients with meaningful improvement. CI confidence interval, EQ-VAS EuroQol visual analogue scale, EWB emotional well-being, FACT-G Functional Assessment of Cancer Therapy–General, FACT-Leu Functional Assessment of Cancer Therapy–Leukemia, FWB functional well-being, HUI health utility index, LeuS leukemia “additional concerns” subscale, OR odds ratio, PRO patient-reported outcome, PWB physical well-being, SWB social/family well-being, TOI trial outcome index, TS total score.

Back to article page